Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAFE-LYSE: Low-dose tPA for Acute PE
NCT03988842Phase 4Terminated
- Start
- Jul 2019
- Primary completion
- Apr 2020
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in pulmonary embolism (PE) comparing Alteplase & Unfractionated Heparin & Apixaban with Placebo & Unfractionated Heparin & Apixaban (2 arms). Primary endpoint: Change in Extent of Clot Lysis at 24 hours. Started Jul 2019; status: terminated.
02
Drugs
tissue-plasminogen activator
03
Conditions
pulmonary embolism (PE)
Beyond the preview
Go deeper on NCT03988842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03988842.